10-Q quarterly report · filed Nov 12, 2026

Sanara MedTech Inc. (SMTI) Q3 2026 10-Q Quarterly Report

Short answer

Sanara MedTech Inc. (SMTI) filed its Q3 2026 10-Q quarterly report on Nov 12, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $28M (up 8.1% year over year) with net income of −$1M.

Q3 2026 key financials · XBRL

Revenue
$28M
+8.1% YoY · +1.0% QoQ
Net income
−$1M
+95.4% YoY · −211.7% QoQ
Operating margin
2.6%
Gross margin
92.6%

Source: XBRL data from the Sanara MedTech Inc. (SMTI) Q3 2026 10-Q on SEC EDGAR. USD.

Sanara MedTech Inc. Q3 2026 10-Q analysis

AI summary of MD&A and risk factor updates

Management Discussion & Analysis

  • Revenue $28.4M, up 8% YoY from $26.3M, driven by soft tissue repair sales up 10% to $25.7M
  • Gross margin approximately 93% vs 93% YoY, with bone fusion sales down 5% to $2.8M
  • Net loss from continuing operations $1.3M vs $0.8M net income, Adjusted EBITDA $5.6M vs $4.9M
  • Cash $16.8M vs $16.6M at December 31, 2025, operating cash flow $3.5M versus $2.8M YoY
  • Outlook: cash expected to fund operations, merger costs and capital expenditures for at least 12 months; FTC Second Request extends merger review

Risk Factors

  • Newly added merger risk: FTC Second Request received October 15, 2026, extending HSR waiting period until 30 days after substantial compliance
  • Regulatory risk: FTC may withhold authorization or impose conditions, restrictions, or costs that delay or prevent completion
  • Financial risk: Failed merger could trigger a $9,660,336 termination fee payable to MiMedx
  • Operational risk: Merger uncertainty may increase employee attrition and hiring costs
  • Legal risk: Shareholder litigation could impose defense costs or obtain an injunction blocking the merger

Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K

Other Sanara MedTech Inc. quarterly reports

Ask about this quarter

Compare quarters, check guidance or see what insiders and funds did around the report.